Current possibilities of therapy for sleep disorders in Parkinson’s disease

Nevrologiâ, Nejropsihiatriâ, Psihosomatika

关键词: parkinson’s disease;    insomnia;    melatonin (melaxen);   

DOI  :  10.14412/2074-2711-2013-2409

来源: DOAJ

【 摘 要 】

The paper presents the specific features of the clinical presentation and pathophysiology of sleep and awakening disorders in patients with Parkinson's disease (PD). It covers the current views of the role of chronobiological mechanisms in the regulation of sleep and awakening in PD. The results of a follow-up of 20 patients (aged 58.56+8.24 years) diagnosed with PD without dementia with subjective nocturnal sleep disorders (disease history was 4.44+3.46 years; PD stage, 2.5+0.47) are given. In addition to antiparkinsonian drugs, melatonin was given in a dose of 3 mg/day. The efficiency of the therapy was evaluated by clinical assessment procedures before and 4—8 weeks after administration of the drug. The therapy outcome was better sleep characteristics in 17 (85%) patients, as evidenced by specialized questionnaires. The positive therapeutic effect as judged by the changes in Parkinson's disease sleep scale scores was shown by improvement of subjective sleep quality, reductions in awakening difficulties, in the total number of nocturnal awakening, in the degree of restlessness in bed, which mimics akathisia, and in the frequency of awakenings that were associated by the patients with urges to urinate (p<0.05).

【 授权许可】

Unknown